Archive by category | - Brady Huggett

How VCs build companies today

We published in the December issue of Nature Biotechnology a news analysis detailing some of the funding models being used by today’s life science investors. Some are looking to expand syndicates, ensuring that funding is there for follow-on rounds. One is sometimes providing huge A rounds by itself. And though many favor an “asset-based” approach, the R&D platform engine is not as dead as might be thought.  Read more

News of the world – in map form

News of the world – in map form

When the news flow supports it, we run a map of sorts in the pages of Nature Biotechnology, rounding up biotech-related items from around the world. This one we published in the December issue, now live on our website. If you’re a subscriber, you can see it here. If not, I’ve pasted it below.  Read more

New Bioentrepreneur article

New Bioentrepreneur article

We’ve posted a new article, Shape Shifting, to the Bioentrepreneur site. The piece examines how to mold a company’s pipeline and opportunities, making it most attractive for partnering or buyout. It was written Bob Baltera, CEO of Amira (at the time), and the title refers to the necessity of changing the shape of a company as it progresses.  Read more

Bioentrepreneur article online

We’ve posted a new article on the Bioentrepreneur website, Headwinds into Opportunity, by Prabhavathi Fernandes. The author is CEO, president and founder of Cempra Pharmaceuticals, and she previously helmed DarPharma, Ricerca Biosciences and Small Molecule Therapeutics. She’s also worked at BMS and Abbott. For more on her background, go here.  Read more

New Bioentrepreneur article

Any conversation on antisense should heavily feature Isis and Crooke: Isis is responsible for the first antisense product approval, Vitravene, in 1998, and Crooke has been at the helm for more than 20 years. He’s known as a loyal, fair and dynamic leader, and we “flagged him in our ’Who’s Who in Biotech’ “:http://www.nature.com/nbt/journal/v24/n3/full/nbt0306-291.html feature in 2006.  Read more

Your questions, answered (or at least discussed)

Your questions, answered (or at least discussed)

A Trade Secrets reader recently emailed me to ask if we might supply a post on this question: “How would an entrepreneur or small biotech raise funding, after having biological proof of concept?”  … Read more

New Bioentrepreneur article

We’ve put a new article on the Bioentrepreneur site, written by Simcha Jong. His piece, Commercializing a disruptive technology, offers perspective and advice to bioentrepreneurs developing new technologies. It is broken loosely into two parts, covering product and platform strategies.  Read more

Talent is Talent

Talent is Talent

Even if the total numbers of attendees at BIO is down from its peak, it’s still an incredibly large gathering of diverse people across the biotech spectrum. The exhibit hall is a good reflection of that. I can remember when the hall was just a collection of simple individual company stands – a few employees in a booth, a poster hanging behind them.  Read more